Clinical trial
Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant…
NCT00356460 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00356460 |
|---|---|
| Title | Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma |
| Official title | A Phase 1 Study of the Safety and Efficacy of GC1008: A Human Anti Transforming Growth Factor-beta (TGFβ) Monoclonal Antibody in Patients With Advanced Renal Cell Carcinoma or Malignant Melanoma |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell, Melanoma |
| Intervention type | Biological |
| Interventions | GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody, GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ ) Monoclonal Antibody |
| Enrollment | 29 |
| Start date | Sep 1, 2006 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Jul 26, 2006 |
| Last update posted | Mar 19, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: